Table 4. Overlapped upstream regulators predicted from UECs and in vivo developed blastocysts.
| Name | Categories | SOV+AI | Score | VIVO | Score |
|---|---|---|---|---|---|
| actinomycin D | biologic drug | Inhi. | –2.48 | Inhi. | –2.55 |
| selenomethylselenocysteine | chemical - endogenous mammalian | Inhi. | –2.24 | Inhi. | –2.45 |
| LY294002* | chemical drug | Inhi. | –2.93 | Inhi. | –2.71 |
| sirolimus | chemical drug | Inhi. | –2.35 | Inhi. | –5.07 |
| U0126* | chemical drug | Inhi. | –2.25 | Inhi. | –2.72 |
| NR4A1 | ligand-dependent nuclear receptor | Inhi. | –2.34 | Inhi. | –2.04 |
| miR-29b-3p* | mature microRNA | Inhi. | –2.91 | Inhi. | –2.42 |
| miR-199a-5p* | mature microRNA | Inhi. | –2.49 | Inhi. | –2.36 |
| let-7* | microRNA | Inhi. | –4.44 | Inhi. | –2.18 |
| RICTOR | other | Inhi. | –5.90 | Inhi. | –5.42 |
| BTNL2 | transmembrane receptor | Inhi. | –2.33 | Inhi. | –2.14 |
| hydrogen peroxide | chemical - endogenous mammalian | Acti. | 3.88 | Acti. | 4.12 |
| phenylephrine | chemical drug | Acti. | 2.24 | Acti. | 2.39 |
| dalfampridine | chemical drug | Acti. | 2.42 | Acti. | 3.61 |
| cisplatin | chemical drug | Acti. | 2.65 | Acti. | 2.19 |
| lipopolysaccharide | chemical drug | Acti. | 3.13 | Acti. | 2.22 |
| daidzein | chemical drug | Acti. | 2.36 | Inhi. | –2.84 |
| forskolin | chemical toxicant | Acti. | 2.03 | Acti. | 2.53 |
| thioacetamide* | chemical toxicant | Acti. | 2.67 | Acti. | 2.95 |
| LIF | cytokine | Acti. | 3.01 | Acti. | 3.26 |
| IL6 | cytokine | Acti. | 3.37 | Acti. | 3.37 |
| AGTR2 | G-protein coupled receptor | Acti. | 2.21 | Acti. | 2.21 |
| Tgf beta | group | Acti. | 2.68 | Acti. | 2.77 |
| ERK* | group | Acti. | 3.44 | Acti. | 2.70 |
| Insulin | group | Acti. | 4.55 | Acti. | 2.33 |
| FGF2 | growth factor | Acti. | 2.09 | Acti. | 2.16 |
| ANGPT2* | growth factor | Acti. | 2.34 | Acti. | 3.16 |
| TGFB1 | growth factor | Acti. | 2.87 | Acti. | 3.13 |
| EGF | growth factor | Acti. | 2.96 | Acti. | 2.74 |
| GDF2* | growth factor | Acti. | 3.22 | Acti. | 3.28 |
| VGLL3 | other | Acti. | 2.00 | Acti. | 2.45 |
| F2* | peptidase | Acti. | 3.34 | Acti. | 2.63 |
| SMAD2 | transcription regulator | Acti. | 2.08 | Acti. | 2.54 |
| SMAD4 | transcription regulator | Acti. | 2.52 | Acti. | 3.28 |
| TP53 | transcription regulator | Acti. | 3.33 | Acti. | 2.01 |
| YAP1* | transcription regulator | Acti. | 3.37 | Acti. | 3.12 |
| STAT3 | transcription regulator | Acti. | 4.18 | Acti. | 3.04 |
| ATF4* | transcription regulator | Acti. | 4.36 | Acti. | 2.57 |
| IRF2 | transcription regulator | Acti. | 2.02 | Inhi. | –2.12 |
| SPI1 | transcription regulator | Acti. | 2.22 | Inhi. | –3.22 |
| IGF1R* | transmembrane receptor | Acti. | 2.71 | Acti. | 2.01 |
SOV+AI, Uterine epithelial cells of super ovulated and artificially inseminated cows; VIVO, in vivo developed blastocysts; Acti, Activated upstream regulators (Acti); Inhi, Inhibited upstream regulators (Inhi). * Prediction of the molecules containing bias factors.